🔗 Share this article

As America continues making sweeping adjustments to its vaccination schedules, one figure has emerged somewhat surprisingly: Dr. Tracy Beth Høeg, an American of Danish descent sports medicine doctor and public health researcher who rose to prominence by casting doubt on Covid vaccines in the pandemic and has zeroed in on potential fatalities after COVID-19 immunization in her brief tenure at the US Food and Drug Administration (FDA).

Proposed Shifts to Pediatric Immunization Program

Health officials planned to reveal sweeping changes to the childhood immunization program earlier this month, aligning the US with the Danish national calendar, sources say – a significant shift that would put the US out of step with much of the world with insufficient data for public health gain. The planned update has been pushed back until the next year.

In place of Vinay Prasad, Høeg is listed to address the audience at the gathering. She was recently named interim head of the FDA’s CDER, the fifth appointee to head the center this year.

Consolidating Power at the Agency

The acting appointment might represent a closer partnership between the pharmaceutical and biologics divisions as Høeg and Dr. Prasad strengthen their influence at the agency – and it suggests a greater focus upon rolling back previously authorized vaccines at the FDA.

Høeg has frequently advocated for halting some pediatric vaccine recommendations in the US to become more in line with the Danish model, a country with nationalized medicine and a population roughly the population of Wisconsin’s.

To date comments, she has kept her attention on vaccines – traditionally the domain of Prasad, head of the FDA’s vaccine center – instead of pharmaceutical oversight.

Questions Over Expertise

Høeg has no obvious background in drug development, regulation or administrative roles, which has been customary for previous leaders of the Center for Biologics Evaluation and Research. She has worked at the FDA as a senior adviser to the FDA chief and CBER since spring.

“She doesn’t seem to have the requisite experience” for running the drug-regulation department, stated Jonathan Howard. “She has not conducted a scientific study. She lacks experience in managing a sizeable institution. She lacks background in industry regulation.”

Past heads of CBER would “grasp legal statutes and the research of drug development”, commented Janet Woodcock. “Clearly, she has not acquired the sort of resume that former directors who led the center have had.”

This division has an immense portfolio at the FDA, she stated.

“Many people just focuses on the innovative therapies, but the generic program authorizes numerous generic drugs. There’s a biologic copycat branch, non-prescription drug unit and more, and each of these need to be supervised,” Dr. Woodcock noted. “The thing you don’t keep your eye on, that is precisely what that I always told people is going to come back to haunt you.”

Additionally, a significant leadership aspect to the job, which oversees over 5,000 personnel. “It’s a huge leadership role, if you do it right,” the former official concluded.

Official Statement and Disputed Programs

When asked about concerns about Høeg’s fitness for the role and whether this assignment represents more teamwork among FDA leaders on vaccines, a press secretary responded that the “inquiries stem from incorrect assumptions”.

“Her resume is consistent with the functions of her job,” the official explained, citing the period Dr. Høeg spent guiding the FDA commissioner on “pharmaceutical safety and oversight research, including computerized risk analysis and shot safety tracking”.

As acting director, Dr. Høeg takes over the agency head's new priority voucher program, a controversial one-day medication authorization process that allegedly concerned her former heads. “How are these medications being chosen for this expedited pathway? Who is making the calls?” Dr. Howard asked. “There is a lot of secrecy going on at the FDA right now.”

Overall, he remarked, “the FDA looks to be trending towards laxer rules of most medications, aside from shots.”

Documented History on Vaccines

With vaccines, Høeg has a more established, if troubling, past, Howard have noted. She released a analysis using unconfirmed public submissions to determine the rate of myocarditis following COVID-19 vaccination. She counseled the Florida surgeon general Dr. Joseph Ladapo, who reportedly have modified findings to suggest Covid vaccines are pose a greater threat than they are.

Among her “wish list” for the incoming federal leadership included changing guidelines for new vaccines and halting “optional” immunizations, she remarked following the vote on a podcast. At the FDA, Høeg has reportedly floated the idea of excluding young men from getting COVID-19 vaccinations.

“She’s an thorough ideologue who commences with her conclusions and reverse-engineers to accommodate the data in a extremely deceptive, dishonest fashion,” Dr. Howard argued.

Taking Control and a “Campaign of Retribution”

Dr. Høeg aligned with other skeptics, {like|